These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 16595046

  • 1. Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy.
    Lehtinen M, Idänpään-Heikkilä I, Lunnas T, Palmroth J, Barr E, Cacciatore R, Isaksson R, Kekki M, Koskela P, Kosunen E, Kuortti M, Lahti L, Liljamo T, Luostarinen T, Apter D, Pukkala E, Paavonen J.
    Int J STD AIDS; 2006 Apr; 17(4):237-46. PubMed ID: 16595046
    [Abstract] [Full Text] [Related]

  • 2. Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing.
    Lehtinen M, Apter D, Dubin G, Kosunen E, Isaksson R, Korpivaara EL, Kyhä-Osterlund L, Lunnas T, Luostarinen T, Niemi L, Palmroth J, Petäjä T, Rekonen S, Salmivesi S, Siitari-Mattila M, Svartsjö S, Tuomivaara L, Vilkki M, Pukkala E, Paavonen J.
    Int J STD AIDS; 2006 Aug; 17(8):517-21. PubMed ID: 16925896
    [Abstract] [Full Text] [Related]

  • 3. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
    Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, Iversen OE, Høye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, von Krogh G, Lehtinen M, Paavonen J, Tamms GM, Giacoletti K, Lupinacci L, Esser MT, Vuocolo SC, Saah AJ, Barr E.
    Vaccine; 2007 Jun 21; 25(26):4931-9. PubMed ID: 17499406
    [Abstract] [Full Text] [Related]

  • 4. Understanding long-term protection of human papillomavirus vaccination against cervical carcinoma: Cancer registry-based follow-up.
    Rana MM, Huhtala H, Apter D, Eriksson T, Luostarinen T, Natunen K, Paavonen J, Pukkala E, Lehtinen M.
    Int J Cancer; 2013 Jun 15; 132(12):2833-8. PubMed ID: 23180157
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Human papillomavirus: a vaccine against cervical carcinoma uterine].
    Franceschi S.
    Epidemiol Prev; 2002 Jun 15; 26(3):140-4. PubMed ID: 12197051
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses.
    Barnabas RV, Laukkanen P, Koskela P, Kontula O, Lehtinen M, Garnett GP.
    PLoS Med; 2006 May 15; 3(5):e138. PubMed ID: 16573364
    [Abstract] [Full Text] [Related]

  • 10. Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types 6/11/16/18) vaccine clinical trials.
    Paavonen J, Future II Study Group.
    Curr Med Res Opin; 2008 Jun 15; 24(6):1623-34. PubMed ID: 18435868
    [Abstract] [Full Text] [Related]

  • 11. Prevention of human papillomavirus infections and associated diseases by vaccination: a new hope for global public health.
    Harper DM.
    Public Health Genomics; 2009 Jun 15; 12(5-6):319-30. PubMed ID: 19684444
    [Abstract] [Full Text] [Related]

  • 12. Human papillomavirus vaccine for genotypes 6, 11, 16 and 18: new drug. Cervical cancer prevention: high hopes...
    Prescrire Int; 2007 Jun 15; 16(89):91-4. PubMed ID: 17582921
    [Abstract] [Full Text] [Related]

  • 13. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
    David MP, Van Herck K, Hardt K, Tibaldi F, Dubin G, Descamps D, Van Damme P.
    Gynecol Oncol; 2009 Dec 15; 115(3 Suppl):S1-6. PubMed ID: 19217149
    [Abstract] [Full Text] [Related]

  • 14. Eligibility and willingness of young Icelandic women to participate in a HPV vaccination trial.
    Gudmundsdóttir T, Tryggvadóttir L, Allende M, Mast TC, Briem H, Sigurdsson K.
    Acta Obstet Gynecol Scand; 2003 Apr 15; 82(4):345-50. PubMed ID: 12716319
    [Abstract] [Full Text] [Related]

  • 15. Prevalence and incidence of HPV genital infection in women.
    Velicer C, Zhu X, Vuocolo S, Liaw KL, Saah A.
    Sex Transm Dis; 2009 Nov 15; 36(11):696-703. PubMed ID: 19652630
    [Abstract] [Full Text] [Related]

  • 16. Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives.
    Insinga RP, Dasbach EJ, Elbasha EH, Liaw KL, Barr E.
    Cancer Epidemiol Biomarkers Prev; 2007 Apr 15; 16(4):709-15. PubMed ID: 17416761
    [Abstract] [Full Text] [Related]

  • 17. Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine.
    Villa LL.
    Int J Infect Dis; 2007 Nov 15; 11 Suppl 2():S17-25. PubMed ID: 18162241
    [Abstract] [Full Text] [Related]

  • 18. Long-term efficacy of human papillomavirus vaccination.
    Ault KA.
    Gynecol Oncol; 2007 Nov 15; 107(2 Suppl 1):S27-30. PubMed ID: 17938016
    [Abstract] [Full Text] [Related]

  • 19. Improving adolescent health: focus on HPV vaccine acceptance.
    Zimet GD.
    J Adolesc Health; 2005 Dec 15; 37(6 Suppl):S17-23. PubMed ID: 16310137
    [Abstract] [Full Text] [Related]

  • 20. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening.
    Arbyn M, Dillner J.
    J Clin Virol; 2007 Mar 15; 38(3):189-97. PubMed ID: 17258503
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.